Susan Fox

Susan Fox, PhD, ChB, MB

Translational studies of new treatments for movement disorders, including phase II and phase IIII clinical studies.
Semin Neurol. 2017 Apr;37(2):147-157
Freitas ME, Hess CW, Fox SH
ACS Chem Neurosci. 2017 May 01;:
Huot P, Sgambato-Faure V, Fox SH, McCreary AC
Br J Haematol. 2017 Apr 25;:
Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S, van der Jagt RHC, Copeland A, Potvin D, Chao R, Younes A
Mov Disord. 2017 Mar 30;:
Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J
Curr Neurol Neurosci Rep. 2017 Jan;17(1):3
Lim SY, Tan AH, Fox SH, Evans AH, Low SC
JAMA Neurol. 2016 Dec 12;:
Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R
Cutis. 2016 Oct;98(4):E10-E12
Fox SH, Elston DM
Mov Disord. 2016 Oct 18;:
Norris SA, Jinnah HA, Espay AJ, Klein C, Brüggemann N, Barbano RL, Malaty IA, Rodriguez RL, Vidailhet M, Roze E, Reich SG, Berman BD, LeDoux MS, Richardson SP, Agarwal P, Mari Z, Ondo WG, Shih LC, Fox SH, Berardelli A, Testa CM, Cheng FC, Truong D,...
CNS Drugs. 2016 Oct 14;
Freitas ME, Ruiz-Lopez M, Fox SH
Can J Neurol Sci. 2016 Aug 12;:1-6
Bruno VA, Fox SH, Mancini D, Miyasaki JM

Pages